Advertising
Supported by
By Reuters
DUBAI – G42 Healthcare of Abu Dhabi signed an initial agreement with NanoScent of Israel to develop, distribute and manufacture a device that detects COVID-19 in expiring air, official United Arab Emirates news firm WAM reported on Wednesday.
The Memorandum of Understanding (MOU) is the latest in a series of agreements between Emirati and Israeli corporations to combat the pandemic, which the two countries said was a precedent in a whole last Thursday by pronouncing a normalization of diplomatic relations.
The test, called Scent Check, will provide effects in 30 to 60 seconds, WAM said, adding that the G42 will go through thousands of tests for the device in the coming weeks.
“The non-invasive nature and speed of effects give Scent Check the ability to reshape the diagnostics industry globally,” WAM said. The device captures exhaled air and analyzes the “volatile biological compounds” provided by the device’s learning, he said.
On Saturday, Emirati national investment company APEX signed a “strategic industry agreement” with Tera Group of Israel to cooperate in coronavirus-related studies and development, adding a device.
Israeli organization Pluristem said Monday that she would marry the Abu Dhabi Stem Cell Center (ADSCC) to expand treatments for diseases such as COVID-19.
Prior to the standardization agreement, two state-owned Israeli defense contractors announced partnerships with the G42 in July to expand technologies to combat coronavirus.
(Reporting through Samar Hassan, written through Nafisa Eltahir, edited through Chris Reese, Kirsten Donovan)
Advertising